# FDA recall D-0476-2017

> **Actavis Inc** · Class II · drug recall initiated 2017-01-30.

## Product

Glipizide extended-release tablets, 2.5mg, 30-count bottle,  Rx Only,  Manufactured By Patheon Pharmaceuticals Inc Cincinnati OH 45237 USA, NDC 0591-0900-30, UPC 3-0591090030-4

## Reason for recall

Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.

## Distribution

Nationwide in US

## Key facts

- **Recall number:** D-0476-2017
- **Recalling firm:** Actavis Inc
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2017-01-30
- **Report date:** 2017-02-22
- **Termination date:** 2018-03-13

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Parsippany, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0476-2017

## Citation

> AI Analytics. FDA recall D-0476-2017. Retrieved 2026-06-02 from https://api.ai-analytics.org/recall/D-0476-2017. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*